Imron Aly, JD, partner at Schiff Hardin LLP, discusses the Biosimilar Action Plan's key features.
Transcript:
What are the key features of the Biosimilar Action Plan?
I would say there are 3 features of the plan that have caught my eye. One is education, 2 is interchangeability, and 3 is international data sharing.
For the first point for education that is key in the biosimilars world because the US has waited for regulatory agencies abroad to really take the lead and test and determine what would be acceptable to the market and to physicians. So in the US, part of the plan is to improve the education and outreach so everybody will have more knowledge about what’s happening around the world and what can happen here too.
The second part for interchangeability--what’s very important for any generic drugs to be motivated--is to be interchangeable for the brand and that way, so that there’s a prescription for the brand of course it can be interchangeable with and substituted by a generic. That is proven to be a high hurdle to biosimilars and part of the plan is meant to address that feature as well.
The third part is international outreach, and this is important, because the plan is trying to get information from other agencies, particularly the [European Medicines Agency, EMA] in Europe, to make sure that what they are doing is working and learn from it and actually try to implement it here in the United States.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.